Gen Ilac signs supply and distribution deal with Incyte
Gen Ilac secures exclusive rights for two Incyte medicines in Turkey and Azerbaijan under a five-year agreement.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Gen Ilac ve Saglik Urunleri Sanayi Ticaret A.S. signed a supply and distribution agreement with Incyte on Oct. 9, Reuters reports.
Under the deal, Gen Ilac received exclusive rights to register, sell, market and distribute Niktimvo (axatilimab) in Turkey, as well as Opzelura (ruxolitinib) in Turkey and Azerbaijan.
The agreement will remain in effect for five years from the first commercial sale.
why it matters
The deal expands Gen Ilac’s product portfolio and gives it exclusive commercialization rights in Turkey and Azerbaijan.
instruments
sources
- Gen Ilac Says It Signs Supply And Distribution Agreement With Incyte On Oct 9 — Reuters, 12 October 2026 at 08:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗